HDAC inhibitors such as vorinostat and belinostat have previously been used in pre-clinical models to reduce RAS pathway signaling by multiple laboratories including our own, most commonly as part of a cancer drug combination (Morelli et al., 2012; Malone et al., 2017; Das et al., 2018; Yamada et al., 2018; He et al., 2019). The gene discussed is HDAC9; the disease is cancer.